NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Santana-Hernández, Sara
• dc.contributor.author Suárez Olmos, Jesús
• dc.contributor.author Servitja Tormo, Sonia
• dc.contributor.author Berenguer-Molins, Pau
• dc.contributor.author Costa García, Marcel, 1989-
• dc.contributor.author Comerma Blesa, Laura, 1983-
• dc.contributor.author Rea, Anna
• dc.contributor.author Perera Bel, Júlia
• dc.contributor.author Menendez Romero, Silvia
• dc.contributor.author Arpí Llucià, Oriol
• dc.contributor.author Bermejo, Begoña
• dc.contributor.author Martínez, María Teresa
• dc.contributor.author Cejalvo, Juan Miguel
• dc.contributor.author Comino-Méndez, Iñaki
• dc.contributor.author Pascual, Javier
• dc.contributor.author Alba, Emilio
• dc.contributor.author López-Botet, M. (Miguel)
• dc.contributor.author Rojo, Federico
• dc.contributor.author Rovira, Ana
• dc.contributor.author Albanell Mestres, Joan
• dc.contributor.author Muntasell i Castellví, Aura, 1972-
• dc.date.accessioned 2024-04-12T05:42:10Z
• dc.date.available 2024-04-12T05:42:10Z
• dc.date.issued 2024
• dc.description.abstract Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies independently from clinicopathological factors in primary HER2-positive breast cancer patients. Understanding the mechanism/s underlying this association would contribute to optimizing patient stratification and provide the rationale for combinatorial approaches with immunotherapy. Methods: We sought to uncover processes enriched in NK cell-infiltrated tumors as compared to NK cell-desert tumors by microarray analysis. Findings were validated in clinical trial-derived transcriptomic data. In vitro and in vivo preclinical models were used for mechanistic studies. Findings were analysed in clinical samples (tumor and serum) from breast cancer patients. Results: NK cell-infiltrated tumors were enriched in CCL5/IFNG-CXCL9/10 transcripts. In multivariate logistic regression analysis, IFNG levels underlie the association between TI-NK cells and pathological complete response to neoadjuvant treatment with trastuzumab. Mechanistically, the production of IFN-ɣ by CD16+ NK cells triggered the secretion of CXCL9/10 from cancer cells. This effect was associated to tumor growth control and the conversion of CD16 into CD16-CD103+ NK cells in humanized in vivo models. In human breast tumors, the CD16 and CD103 markers identified lineage-related NK cell subpopulations capable of producing CCL5 and IFN-ɣ, which correlated with tissue-resident CD8+ T cells. Finally, an early increase in serum CCL5/CXCL9 levels identified patients with NK cell-rich tumors showing good responses to anti-HER2 antibody-based neoadjuvant treatment. Conclusions: This study identifies specialized NK cell subsets as the source of IFN-ɣ influencing the clinical efficacy of anti-HER2 antibodies. It also reveals the potential of serum CCL5/CXCL9 as biomarkers for identifying patients with NK cell-rich tumors and favorable responses to anti-HER2 antibody-based neoadjuvant treatment.
• dc.description.sponsorship AM is supported by ISCiii/FEDER (PI19/00328, PI22/00040 and CIBERONC). The authors are supported by coordinated research projects from Asociación Española contra el Cáncer (GCB15152947MELE). AM and MLB are supported by Generalitat de Catalunya (2017 SGR 888 and 2023 SGR 863). ARe is funded by EC Horizon 2020. Marie Sklodowska Curie-Innovative Training Network (No. 765104; 2018–2021). JA, FR and AR are supported by ISCiii/FEDER (PI18/00006; PI21/00002 and CIBERONC) and by Generalitat de Catalunya (2017 SGR 507; 2021 SGR00776).
• dc.format.mimetype application/pdf
• dc.identifier.citation Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, et al. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Cancer Res. 2024 Jan 3;43(1):10. DOI: 10.1186/s13046-023-02918-4
• dc.identifier.doi http://dx.doi.org/10.1186/s13046-023-02918-4
• dc.identifier.issn 0392-9078
• dc.identifier.uri http://hdl.handle.net/10230/59742
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof J Exp Clin Cancer Res. 2024 Jan 3;43(1):10
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/765104
• dc.rights © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Anti-HER2 antibodies
• dc.subject.keyword Biomarker
• dc.subject.keyword CCL5
• dc.subject.keyword CXCL9
• dc.subject.keyword HER2 positive breast cancer
• dc.subject.keyword IFN-ɣ
• dc.subject.keyword NK cells
• dc.title NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion